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Engineering, Boston University, 8 St.Mary’s Street, Boston, Massachusetts, USA 02215 
ABSTRACT   
Cadmium-free near infrared (NIR) emitting quantum dots (QDs) have significant potential for multiplexed tissue-depth 
imaging applications in the first optical tissue window (i.e., 650 – 900 nm). Indium phosphide (InP) chemistry provides 
one of the more promising cadmium-free options for biomedical imaging, but the full tunability of this material has not 
yet been achieved. Specifically, InP QD emission has been tuned from 480 – 730 nm in previous literature reports, but 
examples of samples emitting from 730 nm to the InP bulk bandgap limit of 925 nm are lacking. We hypothesize that by 
generating inverted structures comprising ZnSe/InP/ZnS in a core/shell/shell heterostructure, optical emission from the 
InP shell can be tuned by changing the InP shell thickness, including pushing deeper into the NIR than current InP QDs. 
Colloidal synthesis methods including hot injection precipitation of the ZnSe core and a modified successive ion layer 
adsoption and reaction (SILAR) method for stepwise shell deposition were used to promote growth of core/shell/shell 
materials with varying thicknesses of the InP shell. By controlling the number of injections of indium and phosphorous 
precursor material, the emission peak was tuned from 515 nm to 845 nm (2.41 – 1.47 eV) with consistent full width half 
maximum (FWHM) values of the emission peak ~0.32 eV. To confer water solubility, the nanoparticles were encapsulated 
in PEGylated phospholipid micelles, and multiplexing of NIR-emitting InP QDs was demonstrated using an IVIS imaging 
system. These materials show potential for multiplexed imaging of targeted QD contrast agents in the first optical tissue 
window.  
Keywords: near infrared imaging, quantum dots, semiconductor, nanoparticle, tissue-depth imaging, photoluminescence, 
fluorescence 
 
1. INTRODUCTION  
Personalized medicine has emerged as an exceptionally powerful tool in treating intransigent diseases. For example, 
molecularly targeted treatments like the antibody-based pharmaceutical trastumazab (brand name Herceptin) specifically 
treats breast tumors that everexpress human epidermal growth factor receptor 2 (HER2).1,2 Wonder drugs, like Herceptin 
and others like it, though not quite tailor made are indicated for very specific patient populations as the drugs have highly 
specific therapeutic mechanisms.3,4 As such for these drugs to ultimately be successful the patient’s disease status has to 
be known very exactly.5,6 Currently surgical biopsies are the gold standard. These biopsies are then stained, or genotyped 
or both. While this technique allows physicians to determine the cancer subtype and bio markers present in the extracted 
sample, this sample is often not representative of the full tumor heterogeneity. It represents just a small part of a much 
larger tumor, and tumors are spatially very heterogeneous.7,8,9,10 Furthermore, surgical biopsies are invasive which makes 
long term monitoring of tumor response to therapy difficult. This represents a major failure of the current gold standard as 
treatments cannot be adjusted rapidly to maximize efficacy in response to tumor evolution. Clearly, there is a significant 
need for a diagnostic tool capable of determining the whole tumor biomarker state accurately and repeatably. While PET, 
CT and MRI can accurately determine the tumor state of one biomarker through specific labeling, they are unable to 
multiplex.11,12,13,14 Therefore, these diagnostic tools are highly inefficient when screening for multiple biomarkers. 
However, multiplexed optical imaging has already been demonstrated, and is a well-known technique in-vitro.15 This 
potential for multiplexing and the lack of ionizing radiation makes optical imaging an ideal diagnostic platform. In order 
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to facilitate optical tumor biopsies the correct fluorescent contrast agent has to be chosen. Such a contrast agent must be 
functionalizable, exhibit long circulation times, be non-toxic and have tunable emission in the NIR wavelength regime.16,17 
Currently there are several NIR emitting dyes and QDs, however, these systems tend to either be toxic, dim, or have very 
large full width half maximums.2 Of the current systems copper doped indium systems are the most promising, yet, these 
systems rely on impurity states to shift the bandgap and so can be more difficult to optimize.18,19,20 To fill the need for a 
bright, narrow, non-toxic and tunable contrast agent, we investigated an inverted type-I indium phosphide quantum dot. 
This synthesis involved depositing monolayers of InP on seed crystals of ZnSe cores and over coating this ZnSe/InP 
nanocrystal with ZnS to enhance chemical robustness and photophysical properties. The emission wavelength of these 
quantum dots were optically tuned by varying the number of successive ion layer adsorption and reaction (SILAR) cycles. 
Using this synthetic strategy we have produced quantum dots with tunable emission wavelengths covering most of the 
visible wavelength regime and all of the NIR-I imaging window. These quantum dots can then be readily encapsulated in 
micelles as a means to confer water solubility without any loss of optical properties. The capacity to generate water soluble 
NIR emitters with tailored emission wavelengths is exciting because it allows for the multiplexed imaging of quantum 
dots targeted to several distinct biomarkers. 
2. METHODS 
2.1 Zinc Oleate synthesis  
The 0.2 M zinc oleate precursor was synthesized by reacting zinc acetate and oleic acid in octadecene (ODE). The solution 
was placed under vacuum, heated to 120 °C, and stirred continuously. Vigorous boiling was observed, due to the release 
of acetic acid during the conversion of zinc acetate to zinc oleate. Once boiling ceased, the reaction flask was backfilled 
with argon and the reaction temperature was increased to 180 °C for 30 minutes under dynamic argon flow to ensure that 
the conversion reaction had gone to completion. The temperature was then reduced to 120 °C, and the solution placed 
under vacuum for 1 hour to remove any residual acetic acid.  
2.2 Indium Oleate synthesis  
The 0.2 M indium oleate precursor was synthesized by reacting oleic acid with indium acetate in ODE. The solution was 
placed under vacuum, heated to 120 °C, and stirred continuously. The solution exhibited vigorous bubbling during the 
conversion of indium acetate to indium oleate as acetic acid was released. Once the solution ceased to boil, the reaction 
flask was placed under active argon flow and the reaction temperature was increased to 160 °C for 20 min to ensure that 
the conversion reaction had gone to completion. The temperature was returned to 120 °C, and the reaction was placed 
under vacuum for 1 hour to remove any residual acetic acid.  
2.3 Sulfur in ODE synthesis  
A 0.2 M sulfur solution in ODE (S8/ODE) was synthesized by dissolving sulfur in ODE. The reaction solution was heated 
to 120 °C and placed under vacuum for 2 hours until the sulfur fully dissolved. The reaction flask was backfilled with 
argon and the temperature was then reduced to 80 °C, and allowed to stir overnight.  
2.4 Diphenyl phosphine selenide synthesis 
DPP:Se was synthesized as previously described.21 Selenium pellets were added to a solution of DPP in anhydrous toluene. 
The reaction was heated until it started gently boiling, and was refluxed at this temperature (114 °C) with a Findenser 
Super Air Condenser for 16 hours. Next, the reaction flask was transferred to a rotary evaporator and the toluene gently 
evaporated, yielding large flakey crystals of DPP:Se. These crystals were collected and washed with cold toluene over a 
Buchner funnel. The resulting purified DPP:Se was a clear white powder. 
2.5 ZnSe nanocrystal synthesis 
Zinc selenide (ZnSe) cores were synthesized according to a protocol previously described in literature.22 In a reaction flask 
under an inert atmosphere, 0.2 M zinc oleate was heated to 80 °C, and DPP was added to increase the reactivity of the zinc 
oleate. Next, 0.15 M DPP:Se dissolved in toluene was added to the reaction flask. Vacuum was applied for 5 min to remove 
the toluene before the solution was placed under active argon flow. The temperature was increased at a rate of 10 °C per 
min until a temperature of 220 °C was reached, at which point the reaction was allowed to proceed for 15 min to 
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completion. The resulting cores were brought into a glovebox and excess reactants were removed by ethanol precipitating 
the ZnSe cores and discarding the supernatant. ZnSe cores were characterized using transmission electron microscopy 
(TEM) and absorbance spectroscopy (both described below). The ZnSe core diameter was determined from manual sizing 
of TEM images. The ZnSe core concentration was calculated using the Beer-Lambert Law after linearly extrapolating the 
molar extinction coefficient from a literature reference value for 3.7 nm diameter ZnSe cores with a 1S absorbance peak 
at 390 nm (ε390 nm = 1.8*105 L M-1 cm-1).23 This extrapolation was carried out assuming a linear relationship between the 
1S absorbance peak location and molar extinction coefficient.24 For example, ZnSe cores with a 1S absorbance peak at 
354 nm and a diameter of 3.4 nm were assumed to have a molar extinction coefficient of ε354 nm = 1.6 *105 L M-1 cm-1.  
2.6 Heterostructured Quantum Dots 
Indium phosphide (InP) shells were deposited on the ZnSe cores using a modified successive ion layer adsorption and 
reaction (SILAR) scheme as seen in Figure 1, where one half atomic monolayer is added at a time. Six of the seven QDs 
presented here (QD515, QD555, QD595, QD675, QD740, and QD770) were synthesized with identical procedures on the 
same ZnSe cores, but with varying rounds of SILAR. First, 150 nmol of 3.4 nm diameter ZnSe cores were added to an 
evacuated solution of ODE and 10% oleylamine by volume. The solution was then heated to 150 °C, after which a volume 
of 0.2 M In(OA)3 sufficient to add one monolayer of indium to the ZnSe core was added and allowed to react for 15 
minutes. The same volume of 0.2 M tris(trimethylsilyl)phosphine (TMS)3P was added dropwise, and the reaction was 
heated to 178 °C for a 1 hour anneal. The volume of 0.2 M In(OA)3 and (TMS)3P needed to add the second atomic 
monolayer (and subsequent layers) were similarly calculated, taking the expected increase in particle size into account. 
This procedure was continued iteratively until the desired emission wavelength had been achieved. In order to passivate 
the surface of the quantum dots, a zinc sulfide (ZnS) cap was added. This was accomplished by adding 0.2 M Zn(OA)2 to 
the reaction solution dropwise at 178°C. After addition, the reaction was heated to 220°C followed by a 1 hour anneal 
time. Then sulfur dissolved in ODE (S8/ODE, 0.2 M), was likewise added dropwise and allowed to anneal for 1 hour. Two 
or three rounds of zinc and sulfur deposition were used for these samples. The final sample presented here, QD845, was 
similarly synthesized with multiple minor modifications. Specifically, a different batch of ZnSe cores were though it was 
also 3.4 nm in diameter, the initial reaction solvent comprised 20% oleylamine by volume in ODE, cation anneals were 
2.5 hours long, and the anion precursor was more dilute at 0.1 M (TMS)3P.  
 
Figure 1. Top: A simplified SILAR scheme for the synthesis of ZnSe/InP/ZnS core/shell/shell heterostructures. Bottom: Band diagrams 
(based on bulk bandgap positions) for the heterostructure at each synthetic step.  
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2.7 Micelle encapsulation 
QDs were encapsulated according to literature, with modifications.25 QDs were precipitated with hexane and ethanol (1:3) 
followed by centrifugation to generate a nanocrystal pellet and the supernatant was discarded. The pellet was redispersed 
in chloroform at a concentration of 4 mg/mL. DSPE-PEG2k (Avanti Polar Lipids) was dissolved in chloroform (15 
mg/mL) and added to the QD sample solution at a QD:DSPE-PEG2k ratio of 1:4.5 (by weight) and allowed to interact for 
10 min. This solution was added to a pear shaped flask and rotary evaporated at 70 °C until a thin film formed. Heated 
deionized water (15 mL) and marbles at 70°C were rapidly added to the thin film followed by vigorous swirling of the 
flask to form micelles. The sample was recovered using a syringe and was passed through a 0.22 µm syringe filter to 
remove aggregates. The resulting QD micelles were concentrated using centrifugal filters (100 kDa molecular weight 
cutoff). 
2.8 Characterization 
Quantum dots were characterized to ascertain their size, morphology, crystal structure, and optical properties. Size and 
morphology was determined using transmission electron microscopy (TEM) on a JEOL 2100 imaging system. To prepare 
samples for TEM analysis, a single drop of the sample in hexane was deposited on a copper grid with an ultra thin carbon 
film and allowed to evaporate. The grid was rinsed with hexanes, ethanol, and DI water to remove organic contaminants. 
Image analysis was performed in ImageJ to determine the particle size.  
X-ray diffraction (XRD) was employed in order to determine the crystal structure of the quantum dots. In order to prepare 
samples for XRD, quantum dots in hexanes were dropcast onto a zero background silicone sample holder until a large 
aggregation of quantum dots formed. The aggregate was then analyzed using a Bruker D8 system. Reference diffraction 
lines for ZnSe, InP, and ZnS were generated using the free software PowderCell2.4 downloaded from the Federal Institute 
for Materials Research and Testing (BAM). These reference lines are representative of the idealized positions and 
intensities of the crystallographic peaks for each material’s bulk diffraction.   
Quantum dot optical properties were analyzed to determine their emission wavelength, quantum yield, absorbance spectra, 
and photoluminescence lifetimes. Photoluminescence emission spectroscopy was carried out on quantum dot samples in 
hexane. These samples were loaded into a quartz cuvette and photoluminescence and photoluminesce excitationwere 
measured using a Jobin Yvon Horriba NanoLog spectrophotometer. Absorption spectroscopy was measured on a 
Cary5000 UV/Vis/NIR spectrophotometer. Photoluminescence lifetime measurements were acquired through time-
correlated single photon counting (TCSPC) on a LifeSpec II spectrophotometer with a 405 nm EPL picosecond pulsed 
diode laser using a 1 microsecond pulse period. 
In order to determine the concentration-corrected absorption profile of the quantum dots, known volumes of the reaction 
solutions were diluted in hexanes and the absorbance of this “raw” sample was measured on an Agilent Cary5000 
UV/Vis/NIR spectrophotometer. We estimated the concentration of the QDs in the raw solution by assuming that the final 
number of QD particles is equal to the starting number of ZnSe cores. To ensure that the increase in absorbance does not 
stem from unreacted precursor, the absorbance of cleaned samples (i.e., QDs precipitated and resuspended in hexanes) 
was also measured and compared to the spectra of the raw samples. In order to normalize for the particle concentration of 
the cleaned sample (i.e., to account for a loss of QDs during the purification), we concentration-normalized the “clean” 
spectra by scaling it to the absorbance spectra of the raw samples. The spectra of the raw and cleaned samples overlap 
nearly perfectly (data not shown), indicating that reaction reagents or byproducts are not contributing to the concentration-
normalized absorbance spectra. The absorbance of larger, redder-emitting QDs increases as there is a larger volume of InP 
to contribute to the absorbance. Unwashed sample for QD845 was not available to be included in this analysis. 
2.9 IVIS imaging  
Optical fluorescence images were obtained using the IVIS® Spectrum advanced preclinical optical imaging system (Perkin 
Elmer). Recently sacrificed (under 24 hours) mouse carcasses were chemically shaved using Nair and then injected 
subcutaneously with 10 μL of 0.1 μM micelle-encapsulated QDs in DI water. Mice were injected in three different 
locations with QD675, QD770, and QD845. The injected mice were placed on a heated stage within the IVIS® system 
and imaged using the following excitation and emission filter pairs given in nanometers, 605/700, 710/760, and 745/840, 
respectively. The auto exposure setting of the Living Image software was utilized for each filter pair in order to maximize 
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image quality. Spectral demixing was performed using Living Image software to generate a composite image from each 
of the filter pair images.  
3. RESULTS AND DISCUSSION 
A series of QDs with progressively redder photoluminescence was synthesized through iterative addition of indium and 
phosphorous precursor materials to a solution of ZnSe cores, followed by capping with zinc and sulfer. The resulting 
emission peaks and corresponding absorbance span most of the visible range and extend into the NIR-I window as seen in 
Figure 2. The absorbtion of the particles increases significantly with addition of indium phosphide. As is expected, the 
redder emitting QDs also absorb redder wavelengths. Importantly for the NIR emitters, we are able to excite the particles 
with NIR wavelengths as well, a feature that is important for wide field, one photon tissue depth imaging. 
 
Figure 2: Optical properties of QSs. (a) Concentration-normalized absorbance, (b) photoluminescence lifetime, and (c) 
photoluminescence and photoluminescence excitation. 
 
b
a c
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TEM images show the size and morphology of the QDs. The nanoparticles increase in size with increasing number of 
SILAR rounds as seen in Figure 3; however, this increase in size was considerably less than what it was calculated to be 
if each SILAR round added one unit cell. There are several possible explanations for why the total size of the particles is 
less than is expected for the planned core/shell/shell heterostructures. It is possible that necessary assumptions made to 
determine ZnSe core concentration was not accurate, leading to a larger than expected number of ZnSe cores in the reaction 
solution and subsequently lower than expected InP shell coverage. It is also possible that the reaction yield was low, again 
leading to less InP coverage than desired. Alternatively, InP nucleation could lead to the presence of InP/ZnS core/shells 
in the solution or etching of the ZnSe core during the reaction could have reduced the size of the ZnSe core in the final 
product.  
Quantum dot morphology was difficult to ascertain due to the small size of the material, the relatively low electron density 
of indium phosphide and the instability of indium during beam bombardment. However, particles appeared generally 
spherical, with some polydispersity in both size and shape of the particles as seen in Figure 3. In order to investigate the 
crystal structure of the quantum dots XRD was carried out on drop cast thin films. The XRD spectra indicates a zincblende 
crystal structure for all samples and the zinc selenide spectra matches its reference well. The XRD spectra for QD550 can 
be seen shifting from the ZnSe crystal structure of the core towards ZnS peaks at higher 2θ values. Indicating that we are 
successfully capping the QDs with ZnS, and that by volume there is more ZnS than InP. For the remaining QD samples, 
the XRD spectra shifts to lower 2θ consistent with InP but are still shifted right from the reference pattern. The higher 2θ 
value peaks narrow from QD 555 to QD770 indicating that the crystal size is increasing.  
 
Figure 3. A) XRD spectra of the seed ZnSe cores and representative quantum shells generated from dropcast thin films. B) Particle size 
histrogram based on sizes determined by TEM analysis. C) Representative size-matched TEM images.  
 
In order for quantum dots to be an effective contrast agent for optical biopsies they have to retain their optical properties 
on being transferred from the organic phase to the aqueous phase. The quantum yield of the quantum dots was unaffected 
by transfer to aqueous media using a lipid-micelle coating, as was the shape and position of the emission peak (data not 
shown). To evaluate the performance of the quantum dots in tissue-depth imaging, they were injected into the mammary 
fat pads and subcutaneously in a mouse cadaver. The mouse was then imaged using selected emission and excitation filter 
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sets to allow for the signal from the quantum dots to be demixed as seen in Figure 4. We were able to demix three distinct 
quantum dots emitting in the NIR-I window from the same mouse at 0.1 μM quantum dot concentrations.   
Figure 4. QD Imaging. (a) The tunability of the InP QDs is seen with this image taken under UV illumination with the NIR filter 
removed from a standard digital camera. (b) Spectrally demixed image of three NIR-emitting lipid-PEG-coated QSs injected in the 
mammary fat pad (QS675 and QS770) and subcutaneously (QS845) in a mouse cadaver. Images taken using epi-illumination on an 
IVIS Spectrum with excitation (ex) and emission (em) filters ex605/em700, ex710/em760, and ex745/em840 for the QS675, QS770, 
and QS845, respectively, with the auto-exposure setting. Spectral demixing was performed using Living Image software to generate a 
composite image from each of the filter pair images. Approximately 100 µL 120 nM water-soluble QSs were injected at each site.   
We have demonstrated that three distinct InP QDs can be imaged simultaneously in the NIR-I window. These quantum 
dots are bright, and emit narrowly enough that we can image three of them concurrently with no spectral bleed through at 
tissue depth. Furthermore, the ability to easily visualize all three of the distinct quantum dots indicate that all three of the 
quantum dots will be detectable at relevant concentrations. Taken together with the excellent retention of optical properties 
on transfer into aqueous solutions, these InP QDs have the potential to serve as multiplexed, targeted optical contrast agent 
for tumor depth imaging. A critical advantage of the QDs presented here is that they exhibited redder (i.e., deeper NIR) 
emission than previsously published reports of traditional InP/ZnS or InP/ZnSe QDs. This shows potential for these 
materials, free of toxic heavy metals, to be developed into improved optical contrast agents for tissue depth imaging.  
4. CONCLUSION 
Inverted type-I InP quantum dots exhibit excellent optical properties in the NIR-I window. The ability to tune the emission 
peaks of these quantum dots synthetically allows for the multiplexed imaging of three distinct emitters at tissue depth in 
the NIR-I window.  The future of medical optical imaging is in the NIR-I and NIR-II windows, as such the ability to 
generate emitters in these ranges at will is extremely exciting. These quantum dots can be rendered water soluble while 
retaining their optical properties, and confer chemical handles for functionalization as well as low non-specific binding.  
In synergy these factors make inverted type-I InP quantum dots an excellent system for the multiplexed imaging of cancer 
biomarkers in tumors and therein enhancing the therapeutic potential of personalized medicine. 
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